Know-how of Target Discovery (with Innovative Target Discovery Platform for Metabolic Diseases, iClue-TDMD)
[Speaker] Cheol Soo Choi / Gachon Univ., Korea
Comparing Platforms: siRNA, ASO, Ab, and Compound for the Treatment of Dyslipidemia
[Speaker] Jeong-Sook Park / Chungnam National Univ., Korea
Which Target would Survive? Metabolism, Inflammation, or Aging?
[Speaker] Kyung A Cho / Chonnam National Univ., Korea
Discussion